focus -WSS

focus

author：comprehensive 2025-09-28 19:24:57 - browse：69

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Kale crackers and hibiscus tea: My five days on a 'fasting diet'

WSS

Crowdfunding for unproven stem cell procedures spreads misinformation

Canadians with cystic fibrosis outlive Americans by a decade

Being 'nonadherent' patient made me a more empathetic doctor

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Skip the lead apron during X

The biotech scorecard for Q3: 15 stock

focus

focus

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pfizer highlights cancer drugs it thinks could reignite investor interest

Peter Hotez and the public health issue of online harassment

In search for therapies for solid tumors, companies turn to claudin

Supreme Court strikes down use of affirmative action

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

How one medical school became remarkably diverse

House looks to weaken Medicare negotiation

focus

Prescription digital therapeutics are key to pharma’s future

A letter from the executive editor: The 2023 STATUS List

AstraZeneca lung cancer study comes in below expectations

What affirmative action's end means to a medical student

What affirmative action's end means to a medical student

An inside look at PIPEs, biotech's buzzy new financing tool

focus

Wikipedia

knowledge

focus